Cancer Immunotherapy
- 1 Edición, Volumen 209 - 24 de octubre de 2024
- Última edición
- Editor: David B. Teplow
- Idioma: Inglés
Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highli… Leer más
Descripción
Descripción
Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment.
Puntos claves
Puntos claves
- Discusses immune surveillance of tumors and how it is compromised
- Presents new approaches to the development and delivery of cancer vaccines and cytotoxic T-cells to the tumor site
- Demonstrates how new molecular biological approaches may augment the efficacy of CAR-T cells and dampen the effects of non-coding RNAs
De interès para
De interès para
Índice
Índice
Matt Giacalone
2. TBA
Tiziana Vavalà
3. Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy
Rio Sugimura and Logan Tang
4. Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?
Moein Ala, Fatemeh Afra, Seyed Parsa Eftekhar and Amir Salehi Farid
5. Rational Design of adjuvants boosts cancer vaccines
Xia Li, Mitsuhiro Ebara, Naoto Shirahata, Tomohiko Yamazaki and Nobutaka Hanagata
6. Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma
Khushwant S. Yadav
7. MAGNETIC NANOPARTICLES: AN EMERGING NANOMEDICINE FOR CANCER IMMUNOTHERAPY
Phoomipat Jungcharoen, Jutatip Panaampon, Thanit Imemkamon and Charupong Saengboonmee
8. TBA
Mi Liu
9. TBA
Sarbajit Mukherjee
10. TBA
Gerardo Cazzato III
11. Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment
Eric Jou
Detalles del producto
Detalles del producto
- Edición: 1
- Última edición
- Volumen: 209
- Publicado: 30 de octubre de 2024
- Idioma: Inglés
Sobre el editor
Sobre el editor
DT
David B. Teplow
David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.